|
1
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thomas JS and Kabbinavar F: Metastatic
clear cell renal cell carcinoma: A review of current therapies and
novel immunotherapies. Crit Rev Oncol Hematol. 96:527–533. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Motzer RJ and Molina AM: Targeting renal
cell carcinoma. J Clin Oncol. 27:3274–3276. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xia M, Yao L, Zhang Q, Wang F, Mei H, Guo
X and Huang W: Long noncoding RNA HOTAIR promotes metastasis of
renal cell carcinoma by up-regulating histone H3K27 demethylase
JMJD3. Oncotarget. 8:19795–19802. 2017.PubMed/NCBI
|
|
6
|
Li JK, Chen C, Liu JY, Shi JZ, Liu SP, Liu
B, Wu DS, Fang ZY, Bao Y, Jiang MM, et al: Long noncoding RNA
MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via
inhibiting NPR3 and activating p38-MAPK signaling. Mol Cancer.
16:1112017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Esteller M: Non-coding RNAs in human
disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long noncoding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shi SJ, Wang LJ, Yu B, Li YH, Jin Y and
Bai XZ: LncRNA-ATB promotes trastuzumab resistance and
invasion-metastasis cascade in breast cancer. Oncotarget.
6:11652–11663. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ong MS, Cai W, Yuan Y, Leong HC, Tan TZ,
Mohammad A, You ML, Arfuso F, Goh BC, Warrier S, et al: ‘Lnc’-ing
Wnt in female reproductive cancers: Therapeutic potential of long
non-coding RNAs in Wnt signalling. Br J Pharmacol. 174:4684–4700.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hosseini ES, Meryet-Figuiere M,
Sabzalipoor H, Kashani HH, Nikzad H and Asemi Z: Dysregulated
expression of long noncoding RNAs in gynecologic cancers. Mol
Cancer. 16:1072017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang F, Li L, Xu H, Liu Y, Yang C, Cowley
AW Jr, Wang N, Liu P and Liang M: Characteristics of long
non-coding RNAs in the Brown Norway rat and alterations in the Dahl
salt-sensitive rat. Sci Rep. 4:71462014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Iguchi T, Uchi R, Nambara S, Saito T,
Komatsu H, Hirata H, Ueda M, Sakimura S, Takano Y, Kurashige J, et
al: A long noncoding RNA, lncRNA-ATB, is involved in the
progression and prognosis of colorectal cancer. Anticancer Res.
35:1385–1388. 2015.PubMed/NCBI
|
|
14
|
Xiong J, Liu Y, Jiang L, Zeng Y and Tang
W: High expression of long non-coding RNA lncRNA-ATB is correlated
with metastases and promotes cell migration and invasion in renal
cell carcinoma. Jpn J Clin Oncol. 46:378–384. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li J, Li Z, Zheng W, Li X, Wang Z, Cui Y
and Jiang X: LncRNA-ATB: An indispensable cancer-related long
noncoding RNA. Cell Prolif. 50:2017. View Article : Google Scholar :
|
|
16
|
Lei K, Liang X, Gao Y, Xu B, Xu Y, Li Y,
Tao Y, Shi W and Liu J: Lnc-ATB contributes to gastric cancer
growth through a MiR-141-3p/TGFβ2 feedback loop. Biochem Biophys
Res Commun. 484:514–521. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zeng X, Hu Z, Ke X, Tang H, Wu B, Wei X
and Liu Z: Long noncoding RNA DLX6-AS1 promotes renal cell
carcinoma progression via miR-26a/PTEN axis. Cell Cycle.
16:2212–2219. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Garding A, Bhattacharya N, Claus R, Ruppel
M, Tschuch C, Filarsky K, Idler I, Zucknick M, Caudron-Herger M,
Oakes C, et al: Epigenetic upregulation of lncRNAs at 13q14.3 in
leukemia is linked to the In Cis downregulation of a gene cluster
that targets NF-κB. PLoS Genet. 9:e10033732013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dowd AA, Homeida S and Elkarem HA:
Detection of chromosome 13 (13q14) deletion among Sudanese patients
with multiple myeloma using a molecular genetics fluorescent in
situ hybridization technique (FISH). Malays J Pathol. 37:95–100.
2015.PubMed/NCBI
|
|
20
|
Lee S, Luo W, Shah T, Yin C, O'Connell T,
Chung TH, Perkins SL, Miles RR, Ayello J, Morris E, et al: The
effects of DLEU1 gene expression in Burkitt lymphoma (BL):
Potential mechanism of chemoimmunotherapy resistance in BL.
Oncotarget. 8:27839–27853. 2017.PubMed/NCBI
|
|
21
|
Li X, Li Z, Liu Z, Xiao J, Yu S and Song
Y: Long non-coding RNA DLEU1 predicts poor prognosis of gastric
cancer and contributes to cell proliferation by epigenetically
suppressing KLF2. Cancer Gene Therapy. 25:58–67. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu Q, Guo L, Jiang F, Li L, Li Z and Chen
F: Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast
cancer cell lines. J Cell Mol Med. 19:2874–2887. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang LL, Sun KX, Wu DD, Xiu YL, Chen X,
Chen S, Zong ZH, Sang XB, Liu Y and Zhao Y: DLEU1 contributes to
ovarian carcinoma tumourigenesis and development by interacting
with miR-490-3p and altering CDK1 expression. J Cell Mol Med.
21:3055–3065. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Du Y, Wang L, Chen S, Liu Y and Zhao Y:
lncRNA DLEU1 contributes to tumorigenesis and development of
endometrial carcinoma by targeting mTOR. Mol Carcinog.
57:1191–1200. 2018. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen JS, Wang Q, Fu XH, Huang XH, Chen XL,
Cao LQ, Chen LZ, Tan HX, Li W, Bi J and Zhang LJ: Involvement of
PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in
hepatocellular carcinoma: Association with MMP-9. Hepatol Res.
39:177–186. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ellinger J, Blondeau JJC, Deng M, Syring
I, Schrödter S, Schmidt D, Perner S and Müller SC: 863
Identification and functional analysis of novel long non-coding
RNAs in clear cell renal cell carcinoma. Eur Urol Suppl.
14:e8632015. View Article : Google Scholar
|
|
28
|
Kwong LN and Davies MA: Navigating the
therapeutic complexity of PI3K pathway inhibition in melanoma. Clin
Cancer Re. 19:5310–5319. 2013. View Article : Google Scholar
|
|
29
|
Guo H, German P, Bai S, Barnes S, Guo W,
Qi X, Lou H, Liang J, Jonasch E, Mills GB and Ding Z: The PI3K/AKT
pathway and renal cell carcinoma. J Genet Genomics. 42:343–353.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sathe A and Nawroth R: Targeting the
PI3K/AKT/mTOR pathway in bladder cancer. Methods Mol Biol.
1655:335–350. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Diehl JA: Cycling to Cancer with Cyclin
D1. Cancer Biol Ther. 1:226–231. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qie S and Diehl JA: Cyclin D1, cancer
progression, and opportunities in cancer treatment. J Mol Med
(Berl). 94:1313–1326. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tavares MR, Pavan IC, Amaral CL,
Meneguello L, Luchessi AD and Simabuco FM: The S6K protein family
in health and disease. Life Sci. 131:1–10. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bates RC and Mercurio A: The
epithelial-mesenchymal tansition (EMT) and colorectal cancer
progression. Cancer Biol Ther. 4:365–370. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nakajima S, Doi R, Toyoda E, Tsuji S, Wada
M, Koizumi M, Tulachan SS, Ito D, Kami K, Mori T, et al: N-cadherin
expression and epithelial-mesenchymal transition in pancreatic
carcinoma. Clin Cancer Res. 10:4125–4133. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mao XW, Xiao JQ, Xu G, Li ZY, Wu HF, Li Y,
Zheng YC and Zhang N: CUL4B promotes bladder cancer metastasis and
induces epithelial-to-mesenchymal transition by activating the
Wnt/β-catenin signaling pathway. Oncotarget. 8:77241–77253. 2017.
View Article : Google Scholar : PubMed/NCBI
|
